ArticleCommunications biology2019
The repurposing of type I-E CRISPR-Cascade for gene activation in plants.
Article in Communications biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 68 citations in OpenAlex.
- Versatile genome editing using Type I-E CRISPR-Cas3 in rice.Plant & cell physiology · 2026Article
- Dystrophin Restorative and Compensatory Gene Addition Therapies for Duchenne Muscular Dystrophy: Could CRISPRa Provide a Realistic Alternative?Muscles (Basel, Switzerland) · 2025Review
- And… cut! - how conformational regulation of CRISPR-Cas effectors directs nuclease activity.The Biochemical journal · 2025Review
- Programmable genome engineering and gene modifications for plant biodesign.Plant communications · 2025Review
- Biochemical plasticity of the Escherichia coli CRISPR Cascade revealed by in vitro reconstitution of Cascade activities from purified Cas proteins.The FEBS journal · 2024Article
- Research Progress on the Mechanism and Application of the Type I CRISPR-Cas System.International journal of molecular sciences · 2024Review
- Versatile and efficient mammalian genome editing with Type I-C CRISPR System of Desulfovibrio vulgaris.Science China. Life sciences · 2024Article
- Engineered minimal type I CRISPR-Cas system for transcriptional activation and base editing in human cells.Nature communications · 2024Article
- Exploiting activation and inactivation mechanisms in type I-C CRISPR-Cas3 for genome-editing applications.Molecular cell · 2024Article
- Targeted DNA integration in human cells without double-strand breaks using CRISPR-associated transposases.Nature biotechnology · 2024Article
- Discovery of Diverse CRISPR-Cas Systems and Expansion of the Genome Engineering Toolbox.Biochemistry · 2023Review
- Dynamic interplay between target search and recognition for a Type I CRISPR-Cas system.Nature communications · 2023Article
- A Cas3-base editing tool for targetable in vivo mutagenesis.Nature communications · 2023Article
- CRISPR-Based Genome Editing Tools: An Accelerator in Crop Breeding for a Changing Future.International journal of molecular sciences · 2023Review
- The biology and type I/III hybrid nature of type I-D CRISPR-Cas systems.The Biochemical journal · 2023Review
- Targeted DNA integration in human cells without double-strand breaks using CRISPR RNA-guided transposases.bioRxiv : the preprint server for biology · 2023Article
- An Engineered λ Phage Enables Enhanced and Strain-Specific Killing of Enterohemorrhagic Escherichia coli.Microbiology spectrum · 2022Article
- Allosteric control of type I-A CRISPR-Cas3 complexes and establishment as effective nucleic acid detection and human genome editing tools.Molecular cell · 2022Article
- Expanding the plant genome editing toolbox with recently developed CRISPR-Cas systems.Plant physiology · 2022Review
- Cas11 enables genome engineering in human cells with compact CRISPR-Cas3 systems.Molecular cell · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CRISPR-Cas systems are robust and facile tools for manipulating the genome, epigenome and transcriptome of eukaryotic organisms. Most groups use class 2 effectors, such as Cas9 and Cas12a, however, other CRISPR-Cas systems may provide unique opportunities for genome engineering. Indeed, the multi-subunit composition of class 1 systems offers to expand the number of domains and functionalities that may be recruited to a genomic target. Here we report DNA targeting in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.